Integral Health Asset Management LLC Grows Stake in Elanco Animal Health Incorporated $ELAN

Integral Health Asset Management LLC raised its holdings in Elanco Animal Health Incorporated (NYSE:ELAN) by 128.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 800,000 shares of the company’s stock after buying an additional 450,000 shares during the quarter. Elanco Animal Health comprises 1.1% of Integral Health Asset Management LLC’s investment portfolio, making the stock its 24th largest position. Integral Health Asset Management LLC owned approximately 0.16% of Elanco Animal Health worth $16,112,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. SJS Investment Consulting Inc. lifted its stake in Elanco Animal Health by 2,563.5% in the third quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock worth $28,000 after acquiring an additional 1,333 shares during the period. Huntington National Bank increased its position in shares of Elanco Animal Health by 136.7% during the third quarter. Huntington National Bank now owns 1,882 shares of the company’s stock valued at $38,000 after buying an additional 1,087 shares during the period. Whittier Trust Co. of Nevada Inc. lifted its holdings in Elanco Animal Health by 80.3% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock worth $42,000 after buying an additional 900 shares during the period. Farther Finance Advisors LLC lifted its holdings in Elanco Animal Health by 79.3% in the third quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock worth $43,000 after buying an additional 951 shares during the period. Finally, Fifth Third Bancorp boosted its position in Elanco Animal Health by 3,018.3% during the 3rd quarter. Fifth Third Bancorp now owns 2,900 shares of the company’s stock valued at $58,000 after acquiring an additional 2,807 shares in the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Barclays started coverage on Elanco Animal Health in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $30.00 price target on the stock. Piper Sandler upgraded shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $24.00 to $30.00 in a report on Thursday, January 22nd. Leerink Partners raised their price objective on Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Tuesday, February 24th. Morgan Stanley lifted their price objective on Elanco Animal Health from $22.00 to $24.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 25th. Finally, UBS Group reiterated a “buy” rating on shares of Elanco Animal Health in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $27.67.

Elanco Animal Health Stock Up 1.2%

Elanco Animal Health stock opened at $22.95 on Friday. Elanco Animal Health Incorporated has a 12 month low of $8.02 and a 12 month high of $27.72. The stock has a fifty day simple moving average of $24.52 and a two-hundred day simple moving average of $22.19. The company has a current ratio of 2.17, a quick ratio of 1.08 and a debt-to-equity ratio of 0.60. The firm has a market cap of $11.41 billion, a price-to-earnings ratio of -47.80, a PEG ratio of 2.89 and a beta of 1.83.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Tuesday, February 24th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. The firm had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.09 billion. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The company’s quarterly revenue was up 12.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.14 earnings per share. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. Equities analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.